alt

48th International Liver Congress (EASL 2013)

April 24-28, 2013, Amsterdam

EASL 2013: Direct-acting Antivirals Boost Response to Pegylated Interferon/Ribavirin

For people with chronic hepatitis C who cannot wait for all-oral regimens, interferon-based therapy is still a reality. Researchers at the recent EASL International Liver Congress (EASL 2013) presented promising data showing that several experimental direct-acting antiviral agents (DAAs) can significantly improve response rates without reducing tolerability.alt

Read more:

EASL 2013: Anemia Is a Common Side Effect of First-generation HCV Protease Inhibitors

About half of patients taking boceprevir (Victrelis) or telaprevir (Incivek or Incivo) developed anemia and approximately one-third experienced skin rash, but sustained response rates were high in an analysis of a population representative of people with chronic hepatitis C in North America, researchers reported at the EASL International Liver Congress (EASL 2013) last month in Amsterdam.

alt

Read more:

EASL 2013: Triple Therapy for Hepatitis C Is Effective after Liver Transplantation but Comes with Side Effects

Adding the approved HCV protease inhibitor telaprevir (Incivek or Incivo) to pegylated interferon and ribavirin can increase sustained response rates even for difficult-to-treat liver transplant recipients, but adverse events are common, researchers reported at the EASL International Liver Congress (EASL 2013) last month in Amsterdam.

alt

Read more:

EASL 2013: ACH-3102 and Sovaprevir Show Potent Activity, High Barrier to Resistance in Early Studies

Achillion Pharmaceuticals' second-generation NS5A inhibitor ACH-3102 demonstrated potent activity against genotype 1a and 1b hepatitis C virus (HCV) and can be safely co-administered with the company's investigational protease inhibitor sovaprevir (formerly ACH-1625), according to studies presented at the EASL International Liver Congress (EASL 2013) last month in Amsterdam.

alt

Read more:

EASL 2013: Do Asian Patients Respond Better to Pegylated Interferon for Hepatitis B?

Some Asian people with chronic hepatitis B treated with pegylated interferon may experience better outcomes on certain measures than Caucasians, though overall response rates are similar, according to a comparative analysis presented at the EASL International Liver Congress(EASL 2013) last month in Amsterdam. The study also showed that early hepatitis B surface antigen (HBsAg) decline is a predictor of treatment response in some patients.

alt

Read more: